Biopharma co. CNS Pharmaceuticals highlights European expansion in Q3 results


CNS Pharmaceuticals has continued expanding its proposed clinical trials into Europe, after it acquired the rights to Berubicin in 2021.

Previous Heartland Ventures raises $52M second fund to draw coastal tech to Midwest industry
Next Kennedy Krieger Institute to expand to Southern Maryland